Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Marimed (MRMD) Shares Outstanding (Diluted Average) (2018 - 2025)

Marimed (MRMD) has disclosed Shares Outstanding (Diluted Average) for 8 consecutive years, with $390.1 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 2.9% to $390.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $390.1 million through Dec 2025, up 2.9% year-over-year, with the annual reading at $390.1 million for FY2025, 2.9% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $390.1 million at Marimed, roughly flat from $388.4 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $390.1 million in Q4 2025, with the low at $340.8 million in Q1 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $373.1 million, with a median of $378.9 million recorded in 2021.
  • The sharpest move saw Shares Outstanding (Diluted Average) skyrocketed 53.85% in 2021, then fell 9.53% in 2023.
  • Over 5 years, Shares Outstanding (Diluted Average) stood at $372.4 million in 2021, then grew by 2.12% to $380.3 million in 2022, then decreased by 4.44% to $363.4 million in 2023, then grew by 4.33% to $379.2 million in 2024, then rose by 2.9% to $390.1 million in 2025.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $390.1 million, $388.4 million, and $389.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.